Barry A L, Jones R N, Thornsberry C, Gavan T L, Gerlach E H, Sommer H M
Eur J Clin Microbiol. 1984 Dec;3(6):531-7. doi: 10.1007/BF02013613.
The in vitro activity of 3-0-demethyl fortimicin A was compared to that of amikacin and tobramycin against 5,230 clinical isolates in four institutions. Amikacin and tobramycin were more active than 3-0-demethyl fortimicin A against Pseudomonas aeruginosa and Acinetobacter spp., but all three drugs had similar activity against the Enterobacteriaceae and Staphylococcus aureus. Additional tests with 335 representative gram-negative bacilli compared five different aminoglycosides, demonstrating differences with some isolates. Standardized disk diffusion tests were also performed with 30 micrograms 3-0-demethyl fortimicin A disks, according to the National Committee for Clinical Laboratory Standards. The following interpretive breakpoints are proposed: less than or equal to 11 mm for resistant (MIC greater than or equal to 32 micrograms/ml) and greater than or equal to 15 mm for susceptible (MIC less than or equal to 16 micrograms/ml).
在四个机构中，将3-O-去甲基福提霉素A与阿米卡星和妥布霉素对5230株临床分离株的体外活性进行了比较。阿米卡星和妥布霉素对铜绿假单胞菌和不动杆菌属的活性比3-O-去甲基福提霉素A更强，但这三种药物对肠杆菌科和金黄色葡萄球菌的活性相似。对335株代表性革兰氏阴性杆菌进行的额外试验比较了五种不同的氨基糖苷类药物，结果显示某些分离株存在差异。还根据美国国家临床实验室标准委员会的标准，用含30微克3-O-去甲基福提霉素A的纸片进行了标准化纸片扩散试验。现提出以下解释性断点：耐药（最低抑菌浓度大于或等于32微克/毫升）为小于或等于11毫米，敏感（最低抑菌浓度小于或等于16微克/毫升）为大于或等于15毫米。
